Patients with type 2 diabetes who switched to tirzepatide rather than escalating their dulaglutide dosage had greater weight ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide ...

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide.

The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs ...

A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...